title: The association of CD25 expression on donor CD8+ and CD4+ T cells with graft-versus-host disease after donor lymphocyte infusions.
abstract: OBJECTIVE
  Graft-versus-host disease (GvHD) remains a major complication of allogeneic stem cell transplantation (SCT) and donor lymphocyte infusions (DLI). CD25-expressing donor T cells may be involved in the prevention or induction of GvHD as these cells comprise both CD4 +CD25+ regulatory T (Treg) cells and preactivated CD4+ or CD8+ conventional T cells. Therefore, we evaluated the relationship between CD25-expressing CD4+ and CD8+ donor T cells and the clinical outcome of DLI.
  
  
  METHODS
  We retrospectively studied the DLI products of 47 HLA-identical DLI recipients by FACS analyses. As Treg cells are often identified within the CD4 +CD25hiCD45RB low subset, we determined the frequencies of CD4+ and CD8+ T cells with different expression levels of CD25 and CD45RB.
  
  
  RESULTS
  The frequencies or infused doses of donor CD4 +CD25+ T cells, regardless of their CD25 and CD45RB expression levels, showed no correlation with the clinical outcome in univariate and multivariate analyses. In contrast, elevated frequencies of donor CD8+CD25+ T cells showed significant correlations with grade II-IV acute GvHD. Patients with GvHD also appeared to have received higher doses of CD8+CD25+ cells. Increased frequencies of CD8+CD25+ cells in the DLI products and the infused-doses of these cells also correlated with complete remissions accompanying GvHD. However, there was no correlation between increased levels of CD8 +CD25+ cells with complete remissions achieved in the absence of a clinically apparent acute GvHD.
  
  
  CONCLUSIONS
  Donor CD8 +CD25++ T cells appear to represent a risk factor for GvHD in the DLI setting. Selective depletion of these cells from DLI products may attenuate GvHD without significantly compromising anti-tumor efficacy.
authors.affiliation: Dept. of Hematology, Jordan Laboratory of Hemato-oncology, UniversityMedical Center Utrecht, Utrecht, the Netherlands. t.mutis@azu.nl
authors.forename: Tuna
authors.initials: T
authors.lastname: Mutis
authors.forename: Tineke
authors.initials: T
authors.lastname: Aarts-Riemens
authors.forename: Leo F
authors.initials: LF
authors.lastname: Verdonck
mesh_terms: D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism* / Q000637:transplantation; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism* / Q000637:transplantation; D005260:Female; D005786:Gene Expression Regulation / Q000235:genetics / Q000276:immunology; D006086:Graft vs Host Disease / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D017710:Lymphocyte Transfusion; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis*; D012189:Retrospective Studies; D050378:T-Lymphocytes, Regulatory / Q000276:immunology / Q000378:metabolism; D014019:Tissue Donors
chemical_list: D015375:Receptors, Interleukin-2